Currently, preliminary trials of hormone therapy have shown good preliminary results in MDD, including corticotropin releasing factor antagonists, glucocorticoid receptor antagonists, thyroid hormone-based HPT axis treatments, and estrogen replacement therapy of HPG axis [30]. Here, NR3C1 is linked to major depressive disorder.